Broad targeting of triptolide to resistance and sensitization for cancer therapy

Area of Science:

• Pharmacology
• Oncology
• Natural Products Chemistry

Background:

• Cancer therapy faces challenges due to drug resistance and severe side effects.
• Natural products offer potential as adjuvant therapies due to their multi-target capabilities and lower costs.
• Triptolide, from Tripterygium wilfordii, exhibits potent antitumor activity but is limited by systemic toxicity.

Purpose of the Study:

• To explore the potential of low-dose triptolide as an adjuvant therapeutic agent in cancer treatment.
• To investigate the mechanisms by which triptolide circumvents anticancer drug resistance and enhances therapeutic effectiveness.
• To review the development of triptolide derivatives and delivery systems to improve its clinical applicability.

Main Methods:

• Review of preclinical and clinical evidence on triptolide's adjuvant effects.
• Analysis of molecular mechanisms underlying triptolide's anti-resistance and sensitization properties.
• Examination of synthetic derivatives and novel drug delivery systems for triptolide.

Main Results:

• Low-dose triptolide effectively overcomes resistance to existing anticancer therapies.
• Triptolide enhances the efficacy of conventional anticancer treatments and reduces associated toxicities.
• Mechanisms include modulation of ATP-binding cassette transporters, apoptosis pathways, tumor suppressors, oncogenic factors, and RNA polymerase II complex.

Conclusions:

• Triptolide at low doses represents a promising adjuvant therapy for overcoming cancer resistance and improving treatment outcomes.
• Its unique targets and ability to mitigate toxicity offer advantages over other therapeutics.
• Development of triptolide derivatives and advanced delivery systems holds potential for enhanced clinical use.